Genenta Science Announces 38 Enrolled Patients in Glioblastoma Multiforme Study.

Genenta Science has enrolled 38 patients in a newly diagnosed glioblastoma multiforme study, with 25 receiving Temferon. Two patients have survived three years from surgery and shown possible Temferon-mediated control of disease progression, warranting further investigation. The survival rate at two years for unmethylated MGMT patients remains consistent at 29%, with median overall survival holding steady.

Genenta Science (Nasdaq: GNTA) has released encouraging long-term follow-up data from its TEM-GBM study of Temferon in glioblastoma multiforme (GBM) patients. The study, which enrolled 38 patients with 25 receiving Temferon, reported two significant milestones: two patients survived three years post-surgery, and one showed no disease progression without requiring second-line therapies [1].

Key clinical outcomes include a 29% two-year survival rate for unmethylated MGMT patients, with a median overall survival of 17 months. These figures compare favorably to historical cohorts, where unmethylated MGMT patients typically show a 14% two-year survival rate and a median survival of 13-15 months with standard care [1].

The company has also initiated the TEM-GU Phase 1 study for genitourinary tumors, targeting 12 patients with Metastatic Renal Cell Carcinoma. This trial aims to evaluate Temferon's combination potential with immune checkpoint inhibitors or tyrosine kinase inhibitors [1].

Genenta's long-term follow-up data suggest that Temferon may potentially control disease progression in GBM. However, larger studies are needed to confirm these findings. The 29% two-year survival rate and 17 months median overall survival in unmethylated MGMT patients represent a significant improvement over historical standards [1].

Genenta Science is expanding Temferon's application to genitourinary tumors, particularly Metastatic Renal Cell Carcinoma, with a Phase 1 study actively recruiting. The fixed dose used (4 million modified cells per kg) has already demonstrated safety in GBM trials, reducing certain development risks [1].

Temferon's mechanism of action—reprogramming the tumor microenvironment to promote immune responses—represents an innovative approach to cancer immunotherapy. The acceptance of their research for publication in Science Translational Medicine lends scientific credibility to their platform technology [1].

References:
[1] https://www.stocktitan.net/news/GNTA/genenta-announces-long-term-follow-up-observations-in-brain-tumor-2b7itzkpge6w.html